 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| Company |
About PharmaNeuroBoost
PNB, founded in 2006 by Erik Buntinx, MD-Psychiatrist, CEO,
creates New Chemical Entities out of existing therapeutics
combined with the company’s proprietary technology. This
technology aims to enhance the efficacy of current standard of
care pharmanceuticals used in major psychiatric disorders with a
high unmet medical need. Based on Buntinx' inventions, PNB
has granted composition of matter and method of use patents
for the technology in the US, Canada, Japan and Europe for the
individual compounds in its pipeline.
The company currently has a core group of 7 key top specialists
– Buntinx, Ludo Haazen, MD, CMO, Remi Van Den Broeck, MD-
MSc, CDO, Didier de Chaffoy, PhD, CSO, Philippe Lemmens, PhD,
Director Clinical Development, Lieven Baert, PhD, MBA, Director
CMC and Patricia Baede, PhD, Director Regulatory Affairs – and
uses a virtual model, contracting drug development people in as
required, with an aim to remain dynamic and efficient.
The most advanced product in PharmaNeuroBoost’s pipeline is
PNB01 in the treatment of major depressive disorder. Over its
first five years of life, PharmaNeuroBoost has proved its
innovative fixed-dose combination concepts in preclinical and
clinical proof of concept trials, and has shown support from the
FDA for a pivotal trial that uses a new endpoint demonstrating
superior efficacy over standard of care. During 2011, the
company will initiate phase III trials for PNB01 and phase IIa
trials for PNB02, respectively in the treatment of major
depression and schizophrenia.
PNB’ Business Plan is oriented to collaborate with high value
partners for co-development and/or commercialization of the
late stage products. Like any drug development company,
PharmaNeuroBoost needs to show the efficacy of its products,
and in this case, it faces the additional challenge of that need to
demonstrate superiority over standard of care, rather than
placebo. However, if the products can achieve this, they could
have a potential step up into a large and lucrative market.
PNB, founded in 2006 by Erik Buntinx, MD-Psychiatrist, CEO,
creates New Chemical Entities out of existing therapeutics
combined with the company’s proprietary technology. This
technology aims to enhance the efficacy of current standard of
care pharmanceuticals used in major psychiatric disorders with a
high unmet medical need. Based on Buntinx' inventions, PNB
has granted composition of matter and method of use patents
for the technology in the US, Canada, Japan and Europe for the
individual compounds in its pipeline.
The company currently has a core group of 7 key top specialists
– Buntinx, Ludo Haazen, MD, CMO, Remi Van Den Broeck, MD-
MSc, CDO, Didier de Chaffoy, PhD, CSO, Philippe Lemmens, PhD,
Director Clinical Development, Lieven Baert, PhD, MBA, Director
CMC and Patricia Baede, PhD, Director Regulatory Affairs – and
uses a virtual model, contracting drug development people in as
required, with an aim to remain dynamic and efficient.
The most advanced product in PharmaNeuroBoost’s pipeline is
PNB01 in the treatment of major depressive disorder. Over its
first five years of life, PharmaNeuroBoost has proved its
innovative fixed-dose combination concepts in preclinical and
clinical proof of concept trials, and has shown support from the
FDA for a pivotal trial that uses a new endpoint demonstrating
superior efficacy over standard of care. During 2011, the
company will initiate phase III trials for PNB01 and phase IIa
trials for PNB02, respectively in the treatment of major
depression and schizophrenia.
PNB’ Business Plan is oriented to collaborate with high value
partners for co-development and/or commercialization of the
late stage products. Like any drug development company,
PharmaNeuroBoost needs to show the efficacy of its products,
and in this case, it faces the additional challenge of that need to
demonstrate superiority over standard of care, rather than
placebo. However, if the products can achieve this, they could
have a potential step up into a large and lucrative market.
| © PharmaNeuroBoost 2011 - All Rights Reserved |
|  |  |  |  |  |  |  |  |
| News Highlights |
Publications
September 30th, 2011
First Patients Enrolled
in the PNB01 Phase
III clinical develop-
ment program in
Major Depression
August 23rd, 2011
PharmaNeuroBoost
ready to enter Phase
III development with
PNB01 in Major
Depression
First Patients Enrolled
in the PNB01 Phase
III clinical develop-
ment program in
Major Depression
August 23rd, 2011
PharmaNeuroBoost
ready to enter Phase
III development with
PNB01 in Major
Depression
